0MR5.LSE CellaVision AB
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 1.27%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is 0MR5.LSE undervalued?
Graham numberThe Graham number of CellaVision AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CellaVision AB fundamental analysis
No fundamental analysis for CellaVision AB yet.
CellaVision AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 fo…
Full company profileCellaVision AB financial statements
CellaVision AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 309M | 365M | 462M | 471M | 566M | - |
| Gross Profit | 223M | 271M | 337M | 313M | 392M | - |
| Operating Income | 90.9M | 112M | 127M | 110M | 163M | - |
| Net Income | 69.7M | 88.7M | 99.2M | 89.5M | 125M | - |
| Balance Sheet | ||||||
| Total Assets | 301M | 373M | 642M | 668M | 825M | - |
| Total Liabilities | 59.7M | 82.4M | 293M | 238M | 282M | - |
| Shareholders' Equity | 241M | 290M | 348M | 430M | 543M | - |
| Cash & Short-term Investments | 155M | 169M | 102M | 102M | 130M | - |
| Total Debt | - | - | 123M | 86.9M | 95.8M | - |
| Cash Flow | ||||||
| Operating Cash Flow | 87.9M | 74.1M | 126M | 71.1M | 160M | 137M |
| Capital Expenditure | 29.1M | 3.58M | 2.67M | 8.07M | 13.7M | 23.5M |
| Ratios | ||||||
| ROE | 28.9% | 30.5% | 28.5% | 20.8% | 23.1% | - |
| ROA | 23.2% | 23.8% | 15.5% | 13.4% | 15.2% | - |
| Net Profit Margin | 22.5% | 24.3% | 21.5% | 19.0% | 22.2% | - |
| Debt to Equity | - | - | 0.35x | 0.20x | 0.18x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CellaVision AB dividends
CellaVision AB has not paid dividends in the last 8 fiscal years.
Who owns CellaVision AB
- Insiders 18.94%
- Institutions 71.04%
- Public & others 10.02%
- Free float 19.5M
CellaVision AB company profile
- Company name
- CellaVision AB
- Ticker
- 0MR5.LSE
- ISIN
- SE0000683484
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 252
- Fiscal year end
- December
- Address
- MobilvAegen 12, Lund, Sweden, 223 62
- Phone
- 46 4 64 60 16 00
- Website
- cellavision.com
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
CellaVision AB management
9- Mr. Christer Fahraeus B.Sc. Maths, h.c., MSc Bio Eng, Ph.D.Founder & Director · born 1965
- Mr. Steve FergusonChief Executive Officer
- Ms. Monica JonssonChief Financial Officer · born 1980
- Mr. Julien VeyssyVice President of Operations · born 1983
- Mr. Peter WilsonVice President of Business Development & Global Marketing · born 1967
- Mr. Urban StrindlovVice President of Global Sales · born 1964
- Ms. Anne Safstrom LannerVice President of Human Resources · born 1969
- Ms. Helena RaihleCorporate Communications & Investor Relations
- Lisa Bodily NordqvistCorporate Communications & Investor Relations